Abstract
The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis (P5-1.004)
Neurology, Vol.98(18_supplement)
05/03/2022
DOI: 10.1212/WNL.98.18_supplement.1651
Abstract
Abstract only
Details
- Title: Subtitle
- The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis (P5-1.004)
- Creators
- Gregory Day - Mayo Clinic in ArizonaMaarten Titulaer - Erasmus MCKa-Ho Wong - University of UtahJames Torner - University of IowaMerit Cudkowicz - Massachusetts General HospitalChristopher Coffey - University of IowaCodrin Lungu - NINDS, NIHEric Klawiter - Massachusetts General HospitalJ. Robert Singleton - University of UtahDana Mitchell - Indiana UniversityJanel Fedler - University of IowaDixie Ecklund - University of IowaDavid Klements - Massachusetts General HospitalMichele Costigan - University of IowaStacey Clardy - University of Utah
- Resource Type
- Abstract
- Publication Details
- Neurology, Vol.98(18_supplement)
- DOI
- 10.1212/WNL.98.18_supplement.1651
- ISSN
- 0028-3878
- eISSN
- 1526-632X
- Language
- English
- Date published
- 05/03/2022
- Academic Unit
- Neurology; Epidemiology; Biostatistics; Injury Prevention Research Center; Neurosurgery
- Record Identifier
- 9984539444502771
Metrics
20 Record Views